Per Nilsson
1 – 10 of 114
- show: 10
- |
- sort: year (new to old)
Close
Embed this list
<iframe src=" "
width=" "
height=" "
allowtransparency="true"
frameborder="0">
</iframe>
- 2024
-
Mark
Register data on long-term morbidity after prostate cancer radiotherapy with ultra-hypofractionated (2.5 weeks) vs conventional (8 weeks) treatment schedules
2024) U21 Health Sciences Group 2024 Doctoral Student Forum(
- Contribution to conference › Poster
-
Mark
Ultrahypofractionated Radiation Therapy for Prostate Cancer Including Seminal Vesicles in the Target Volume : A Treatment-planning Study Based on the HYPO-RT-PC Fractionation Schedule
(
- Contribution to journal › Article
-
Mark
Morbiditet från urinvägar och tarm enligt registerdata efter ultrahypofraktionerad strålbehandling för lokaliserad prostatacancer vid 10 år i HYPO-RT-PC-studien
2024) Onkologidagarna 2024(
- Contribution to conference › Poster
-
Mark
Register data on long-term morbidity after prostate ultra-hypofractionation in the HYPO-RT-PC trial
(
- Contribution to conference › Abstract
-
Mark
Dose-volume relationships of planned versus estimated delivered radiation doses to pelvic organs at risk and side effects in patients treated with salvage radiotherapy for recurrent prostate cancer
(
- Contribution to journal › Article
-
Mark
Cost-effectiveness analysis of (accelerated) pre-operative versus (conventional) post-operative radiotherapy for patients with oral cavity cancer in Sweden
(
- Contribution to journal › Article
- 2023
-
Mark
MRI-only radiotherapy from an economic perspective : Can new techniques in prostate cancer treatment be cost saving?
(
- Contribution to journal › Article
-
Mark
Risk of prostate cancer death after radical radiotherapy with neoadjuvant and adjuvant therapy with bicalutamide or gonadotropin-releasing hormone agonists
(
- Contribution to journal › Article
-
Mark
Importance of tumor volume, overall treatment time and fractionation sensitivity for p16-positive and p16-negative oropharyngeal tumors
(
- Contribution to journal › Article
- 2022
-
Mark
Primary tumor volume and prognosis for patients with p16-positive and p16-negative oropharyngeal squamous cell carcinoma treated with radiation therapy
(
- Contribution to journal › Article